Evolution of the Average Target: Myriad Genetics, Inc.

Evolution of the Target Price: Myriad Genetics, Inc.

Changes in Analyst Recommendations: Myriad Genetics, Inc.

424b769f879b56b744feb.FExJL8HWsQI6v40L6LeJrI3NVyZetr9MXJXrtmsPEY8.RhkWbfms_lFqzcNMoeDF9e6GFHAx7vR1aaDahDJbc-dDCCocu-_bUnWLwA~b2fb8c4bcfbe933a856e1ddd9582b6b0
09/09 UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating MT
01/09 Myriad Genetics Shares Fall After Piper Sandler Downgrade MT
01/09 Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight MT
24/02 UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating MT
04/11 UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating MT
07/25/07 UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating MT
06/25/06 Top Midday Gainers MT
22/25/22 Myriad Genetics Shares Fall After Downgrade From Scotiabank MT
21/25/21 Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20 MT
19/25/19 Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating MT
08/25/08 Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform MT
07/25/07 UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating MT
07/25/07 Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22 MT
09/25/09 Guggenheim Downgrades Myriad Genetics to Neutral From Buy MT
13/25/13 Myriad Genetics Shares Rise After Upgrade From Piper Sandler MT
12/25/12 Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 MT
25/25/25 UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating MT
09/24/09 Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30 MT
18/24/18 Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating MT
19/24/19 Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target MT
19/24/19 Morgan Stanley Initiates Myriad Genetics at Equalweight MT
28/24/28 Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target MT
27/24/27 Scotiabank Initiates Myriad Genetics at Sector Outperform MT
13/24/13 Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating MT
29/24/29 Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- -12.78%
+11.95%
+9.79%
-28.27%
-2.38%
+7.16%
+34.91%
-3.28%
+19.67%
Average +4.09%
Weighted average by Cap. +5.28%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
3.860USD
Average target price
3.367USD
Spread / Average Target
-12.78%
High Price Target
5.000USD
Spread / Highest target
+29.53%
Low Price Target
2.000USD
Spread / Lowest Target
-48.19%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. MYGN Stock
  4. Consensus Myriad Genetics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!